title: A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts.
abstract: The insulin-like growth factor-I receptor (IGF-IR) and its ligands (IGF-I and IGF-II) have been implicated in the growth, survival, and metastasis of a broad range of malignancies including pediatric tumors. Blocking the IGF-IR action is a potential cancer treatment. A fully human neutralizing monoclonal antibody, SCH 717454 (19D12, robatumumab), specific to IGF-IR, has shown potent antitumor effects in ovarian cancer in vitro and in vivo. In this study, SCH 717454 was evaluated in several pediatric solid tumors including neuroblastoma, osteosarcoma, and rhabdomyosarcoma. SCH 717454 is shown here to downregulate IGF-IR as well as inhibit IGF-IR and insulin receptor substrate-1 phosphorylation in pediatric tumor cells. IGF-IR and insulin receptor substrate-1 phosphorylation in the tumor cells. In vivo, SCH 717454 exhibits activity as a single agent and significantly inhibited growth of neuroblastoma, osteosarcoma, and rhabdomyosarcoma tumor xenografts. Combination of SCH 717454 with cisplatin or cyclophosphamide enhanced both the degree and the duration of the in vivo antitumor activity compared with single-agent treatments. Furthermore, SCH 717454 treatment markedly reduced Ki-67 expression and blood vessel formation in tumor xenografts, showing that the in vivo activity is derived from its inhibition of tumor cell proliferation and angiogenesis activity.
authors.affiliation: Department of Tumor Biology, Merck Research Laboratory, K15-4-4700, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. yaolin.wang@spcorp.com
authors.forename: Yaolin
authors.initials: Y
authors.lastname: Wang
authors.forename: Philip
authors.initials: P
authors.lastname: Lipari
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Wang
authors.forename: Judith
authors.initials: J
authors.lastname: Hailey
authors.forename: Lianzhu
authors.initials: L
authors.lastname: Liang
authors.forename: Robert
authors.initials: R
authors.lastname: Ramos
authors.forename: Ming
authors.initials: M
authors.lastname: Liu
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Pachter
authors.forename: W Robert
authors.initials: WR
authors.lastname: Bishop
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000276:immunology; D019394:Ki-67 Antigen / Q000096:biosynthesis; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D010766:Phosphorylation; D017526:Receptor, IGF Type 1 / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1